Ortho Clinical Diagnostics Holdings plc (OCDX): Price and Financial Metrics Recent IPO


Ortho Clinical Diagnostics Holdings plc (OCDX): $21.82

0.49 (+2.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

OCDX Stock Price Chart Interactive Chart >

Price chart for OCDX

OCDX Price/Volume Stats

Current price $21.82 52-week high $22.99
Prev. close $21.33 52-week low $15.14
Day low $21.42 Volume 548,500
Day high $22.03 Avg. volume 1,154,756
50-day MA $21.07 Dividend yield N/A
200-day MA $0.00 Market Cap 4.86B

Ortho Clinical Diagnostics Holdings plc (OCDX) Company Bio


Ortho Clinical Diagnostics Holdings plc operates as a holding company. The Company, through its subsidiaries, provides vitro diagnostics products and services to the global clinical laboratory and immunohematology communities. Ortho Clinical Diagnostics Holdings serves customers worldwide.


OCDX Latest News Stream


Event/Time News Detail
Loading, please wait...

OCDX Latest Social Stream


Loading social stream, please wait...

View Full OCDX Social Stream

Latest OCDX News From Around the Web

Below are the latest news stories about Ortho Clinical Diagnostics Holdings plc that investors may wish to consider to help them evaluate OCDX as an investment opportunity.

ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in Canada

Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its semi-automated ORTHO OPTIX™ Reader, which allows lower-volume transfusion labs to elevate their standard of patient care with the quality of results expected of an automated platform, is now available in Canada.

Yahoo | July 26, 2021

Ortho Clinical Diagnostics to Report Second Quarter 2021 Results on August 4, 2021

RARITAN, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it will report results for its second quarter 2021 ended July 4, 2021, after the market close on Wednesday, August 4, 2021. Ortho Clinical Diagnostics will hold a conference call the same day at 5:00 pm ET to discuss the results. Interested parties can access the call and accompanying presentation on the “Investors” porti

Yahoo | July 23, 2021

Ortho Clinical Diagnostics Announces Launch of the Interleukin-6 (IL-6) Reagent Pack, Latest Addition to Ortho''s Critical Care Blood Testing Menu

RARITAN, N.J., July 22, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world''s largest pure-play in vitro diagnostics companies, today announced its VITROS® Immunodiagnostic Products IL-6 Reagent Pack, the latest addition to Ortho''s VITROS® Critical Care menu,

PR Newswire | July 22, 2021

Ortho Clinical Diagnostics Announces Launch of the Interleukin-6 (IL-6) Reagent Pack, Latest Addition to Ortho's Critical Care Blood Testing Menu

Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its VITROS® Immunodiagnostic Products IL-6 Reagent Pack, the latest addition to Ortho's VITROS® Critical Care menu, is now available in EU Countries, U.K. and several ASPAC and LATAM countries.*

Yahoo | July 22, 2021

Blood Transfusion Diagnostics Market to See Massive Growth by 2031 | Grifols S.A., Immucor Inc., Ortho Clinical Diagnostics, Diamond Diagnostics, Abbott Laboratories

The latest insightSLICE research report published on Blood Transfusion Diagnostics promises to cede reliable and clarifying insights appertaining to the real time scenario trajectory concerning the market arena during the speculated forecast period of 2021-2031. Setting forth the risks and opportunities

OpenPR | July 21, 2021

Read More 'OCDX' Stories Here

OCDX Price Returns

1-mo 0.32%
3-mo 10.09%
6-mo 35.53%
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6768 seconds.